In addition to its antifibrinolytic role, PAI-1 has emerged as a profibrotic factor implicated in the pathogenesis of various pulmonary diseases [10], and elevated systemic levels of PAI-1 have been reported in patients with COPD, associated with accelerated lung function decline [11]. This evidence concerns the gene SERPINE1 and lung disorder.